Moderna, Inc. MRNA

Revenue growth is driven by operating spend, with SG&A spending showing a slightly higher revenue elasticity than R&D: a 1% increase in SG&A is associated with about a 1.01% rise in revenue, while 1% more R&D yields about a 0.62% increase. These estimates come from a log-log model estimated on 32 quarters of data, but forecast reliability is weak, with a MAPE of 36.3% and a holdout test error where the model predicted $0.2B but actually delivered $0.7B (about 68% error). The FY outlook shows revenue around $0.8B, down 57.5% year over year, implying meaningful near-term downside unless new products or markets are added. Given the modest elasticity and the weak predictive performance, ROI on R&D and SG&A spending appears uncertain, underscoring the need for better pipeline execution and tighter cost management to support revenue stability.